The breakthrough success of anti–PD-1/PD-L1 immune-checkpoint inhibitor (ICI) treatment has been witnessed in various cancers such as advanced-stage melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC) (Hargadon et al., 2018). This evidence concerns the gene CD274 and renal cell adenocarcinoma.